ALGS — Aligos Therapeutics Income Statement
0.000.00%
- $39.34m
- -$73.17m
- $15.53m
- 12
- 41
- 69
- 35
Annual income statement for Aligos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 4.36 | 13.9 | 15.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 54 | 97.8 | 133 | 111 | 104 |
Operating Profit | -54 | -97.8 | -128 | -97.6 | -88.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -52.2 | -108 | -128 | -95.9 | -86.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -52.3 | -109 | -128 | -96 | -87.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -52.3 | -109 | -128 | -96 | -87.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -52.3 | -109 | -128 | -96 | -87.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.42 | -2.97 | -3.22 | -2.25 | -1.31 |
Dividends per Share |